BIOLASE Stock Forecast, Price & News

4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for BIOLASE in the last twelve months. There are currently 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" BIOLASE stock.
View analyst ratings for BIOLASE or view top-rated stocks.

4 equities research analysts have issued 12 month target prices for BIOLASE's stock. Their BIOL stock forecasts range from $12.00 to $75.00. On average, they predict BIOLASE's stock price to reach $41.50 in the next year. This suggests a possible upside of 841.0% from the stock's current price.
View analysts' price targets for BIOLASE or view top-rated stocks among Wall Street analysts.

BIOLASE's stock was trading at $9.75 at the beginning of 2022. Since then, BIOL stock has decreased by 54.8% and is now trading at $4.41.
View the best growth stocks for 2022 here.

BIOLASE is scheduled to release its next quarterly earnings announcement on Thursday, August 11th 2022.
View our earnings forecast for BIOLASE.

BIOLASE, Inc. (NASDAQ:BIOL) issued its quarterly earnings data on Thursday, May, 12th. The medical technology company reported ($0.81) earnings per share for the quarter. The medical technology company earned $10.17 million during the quarter. BIOLASE had a negative trailing twelve-month return on equity of 62.40% and a negative net margin of 34.03%.
View BIOLASE's earnings history.

Shares of BIOLASE reverse split before market open on Friday, April 29th 2022. The 1-25 reverse split was announced on Friday, April 29th 2022. The number of shares owned by shareholders was adjusted after the closing bell on Friday, April 29th 2022. An investor that had 100 shares of BIOLASE stock prior to the reverse split would have 4 shares after the split.

BIOLASE issued an update on its second quarter 2022 earnings guidance on Thursday, June, 9th. The company provided EPS guidance of for the period. The company issued revenue guidance of $10.50M-, compared to the consensus revenue estimate of $10.20 million.

8 employees have rated BIOLASE CEO Todd Norbe on Glassdoor.com. Todd Norbe has an approval rating of 13% among BIOLASE's employees. This puts Todd Norbe in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies.

Some companies that are related to BIOLASE include Item 9 Labs (INLB), Sonendo (SONX), American Medical Technologies (ADLI), Lancer Orthodontics (LANZ) and Remedent (REMI).
View all of BIOL's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other BIOLASE investors own include Himax Technologies (HIMX), Accelerate Diagnostics (AXDX), Biocept (BIOC), Magnachip Semiconductor (MX), Fluidigm (FLDM), Matinas BioPharma (MTNB), MicroVision (MVIS), Acasti Pharma (ACST), Bionano Genomics (BNGO) and Genius Brands International (GNUS).

BIOLASE trades on the NASDAQ under the ticker symbol "BIOL."

Shares of BIOL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of BIOL stock can currently be purchased for approximately $4.41.

BIOLASE (NASDAQ:BIOL) has a market capitalization of $27.25 million and generates $39.19 million in revenue each year. The medical technology company earns $-16,160,000.00 in net income (profit) each year or ($2.06) on an earnings per share basis.

BIOLASE employs 158 workers across the globe.

BIOLASE's mailing address is 27042 Towne Center Drive Suite 270, Lake Forest CA, 92610. The official website for BIOLASE is www.biolase.com. The medical technology company can be reached via phone at (949) 361-1200, via email at rcaron@dresnerallencaron.com, or via fax at 949-273-6677.